FAQ

Abnormally low creatinine and specific gravity levels may be indicative of a patient having adulterated their urine by diluting it with water. However, it may also be the result of ingestion of very large volumes of fluid. Recommendations; the patient should be retested and asked not to drink large volumes of fluids prior to the urine test.

The Centers for Medicare & Medicaid Services (CMS) regulates all laboratory testing (except research) performed on humans in the U.S. through the Clinical Laboratory Improvement Amendments (CLIA). The purpose of CLIA is to set minimum standards for all laboratories to follow and to determine if laboratories are achieving those standards. Any person or facility that performs laboratory tests on human specimens for the purpose of diagnosis and/or treatment is required by federal law to have a CLIA certificate. Note: Although all clinical laboratories must be properly certified to receive Medicare or Medicaid payments, CLIA has no direct Medicare or Medicaid program responsibilities.

Laboratory testing results are accurate and reliable. The identification of individual drugs at RHB Laboratories is achieved using a highly selective methodology called mass spectrometry (MS), which allows the laboratory to make unequivocal identifications. For this reason, all urine specimens should be submitted to our laboratory for testing, as instant devices such as urine cups or dipsticks do not offer this level of selectivity or accuracy.

We use UPS for all of your shipping needs. No matter where you are in the country, we can receive your sample the next day. In addition, we will provide you with specimen-collection kits that come pre-addressed and ready to ship back to us.

RHB Laboratories supplies everything that you need to do your testing, at no cost to you. If you have never placed an order with RHB Laboratories, contact a member of our sales team or Client Services at 248-557-0411 to get started.

The following are common sample turnaround times for RHB Laboratories:
Urine: 2 business days*
Oral Fluid: 3 business days*
* Request of additional tests not included in the standard panel may extend turnaround time to 3-5 business days.

Confirmation analysis comprises chromatographic separation and mass spectrometry identification to detect and verify the presence of drugs in a specimen. Confirmatory testing is performed utilizing LC/MS, and LC/MS/MS methodologies and encompasses additional steps before and after the actual analysis. These steps include chemical extraction, which is performed prior to analysis in order to remove any interfering substances, data review, and data certification. RHB Laboratories confirmation process ensures that the results we deliver are accurate and precise every time.

For your convenience, reports can be viewed online, faxed, and mailed. If you don't have a username and password for viewing reports online, contact our Client Services Department at 248-557-0411 or admin@rhblab.com to obtain a registration form.

Our full-time toxicologists and chief medical officer are always willing to assist you with the interpretation of results. Simply call Client Services at 248-557-0411. One of our representatives will connect you with an available expert. You may also e-mail questions to admin@rhblab.com

RHB Laboratories is a full-service reference lab. If you have specific needs or are interested in having a test created to meet your specific needs, please contact your sales representative. We will work to satisfy your request in a professional, timely manner.

Interference is an unknown signal that prevents accurate identification of drugs during the confirmation analysis. Its origin cannot be determined, but it may be an endogenous compound (a naturally occurring compound within the body), a prescription medication, or something added to the specimen after collection. In instances where a definite positive or negative result cannot be determined for a drug, the test is conducted a second time. After the second attempt, if the drug in question still cannot be accurately determined, the test for that drug is canceled.

A negative result does not necessarily mean there is zero trace of a drug in a given sample. Rather, it indicates that the drug was not detected above the pre-determined cut-off concentration. For example, a cut-off of 300 ng/mL for benzodiazepines means that the combined total of cross-reacting benzodiazepines in the specimen must be above 300 ng/mL to register on the test and produce a positive result. Specimens that contain a combined total benzodiazepine concentration of fewer than 300 ng/mL will register on the test as negative. Therefore, in some cases, low concentrations may be present, but a negative result shows up on the report and is still considered to be an accurate test result.

Ethanol (drinking alcohol) may be detected in blood and urine after consumption of alcoholic beverages. Blood and urine ethanol concentrations may be very different, depending on the time between ethanol consumption and specimen collection and frequency of urination. The ethanol concentration will often be higher in urine than in blood. In some cases, urine ethanol may be highly positive and the blood completely negative. Therefore, urine ethanol cannot be used to estimate a blood ethanol concentration.

There are two common ways that users attempt to cheat a urine drug test: modify their urine sample with chemicals or drink large amounts of water prior to testing in order to dilute their sample. Many products are available on the Internet claiming to enable a person to produce a negative test result after drug use if that product is added to a urine sample. Most of these products contain strong chemicals known as oxidants, which are capable of modifying the chemical structure of a drug. RHB Laboratories Laboratories tests every urine sample for the presence of oxidants to identify potential adulteration. Dilute specimens are also easily identified at RHB Laboratories by measuring the concentration of creatinine in each sample. Individuals who consume large quantities of water prior to a test in an attempt to dilute their sample will often have abnormally low levels of creatinine. Validation tests such as those described above are performed to identify individuals who are adulterating their urine specimen in this manner.

Self-reporting of drugs has limited validity, and monitoring behavior alone can fail to detect problems revealed by UDTs. Creating a UDT policy in advance and applying it consistently to all patients on opioids may help de-stigmatize the testing. Inform your patient that drug testing is a routine procedure for all patients starting or maintained on opioid therapy and it is an important tool for monitoring the safety of opioid therapy. Possible language for explaining to patients include: Ensures my capacity to provide treatment for your pain while balancing the need for safety. Provide critical information needed to assess the success of your therapy. Prescription medications are a common form of treatment for chronic pain. However, each person reacts differently to them. UDT enables us to identify individual risks related to your medications and avoid problems. Our clinic uses universal precautions in opioid prescribing, which includes UDT. This is the same as wearing gloves on all patients when drawing blood.

No. It is very difficult to correlate urine drug concentration with a patient's dose. UDT can detect the parent drug and/or its metabolite(s) and demonstrate recent use of prescribed drugs and illegal substances. However, it CANNOT determine the amount of drug used and when the last dose was taken, or can it identify the source of the drug.

A small percentage of persons are ultra-rapid metabolizers. They metabolize specific drugs more rapidly than typical patients. It would be rare to take an opioid as prescribed and not be detected in their urine.

This is a complex issue. Marijuana is currently classified as a Schedule 1 drug by the DEA. For that reason, many providers will not prescribe opioids to patients using cannabis. Other providers reference State Medical Marijuana Use laws and feel comfortable prescribing opioids to cannabis users. Some providers adopt a don't ask, don't tell policy, and request the lab to remove marijuana from the UDT so that positive results are not seen. Do your homework and create an office policy. Then disclose this policy to your patients.

Urine testing typically has a 1-3 day window of detection for most drugs depending on dose and individual differences in drug metabolism. Short-acting opioids can be detected if the lab removes the cut-off concentration so that the presence of lower concentrations is detected. If the laboratory uses LC/MS, then it will have a lower limited of detection (LOD) with less interference.

Immunoassays used in drug screening can cross-react with other drugs and vary in sensitivity and specificity. Thus, confirmation with a more accurate method may be required for clinical decision-making. Confirmatory drug testing (LC/MS or GS/MS) of the original specimen is recommended for unexpected results, or in cases where patients are known to be high risk. However, on occasion, even confirmatory testing requires expert assistance for interpretation. Consider consultation with the lab before discussing/confronting the patient with unexpected test results and discontinuing opioid therapy.

No. Random screening based on the frequency recommended in the guideline should suffice for most patients. Those patients who you feel require drug screening on every visit, are perhaps not candidates for chronic opioid therapy.

It depends. Drug testing for clinical compliance, unlike employment testing, does not require a strict chain-of-custody. However, it tampering is a concern, the specimen should be monitored for temperature and/or adulterants. Normal human urine should have a temperature between 90F - 100F, pH between 4.5 - 8.5, and creatinine >20 mg/dL. Be aware that there are multiple websites and devices devoted to getting a clean urine drug screen.